The Certara Blog

Author: Sumeet Bakshi & Artak Khachatryan

Sumeet is VP, Real World Evidences Solutions, in Analytica Laser, Certara’s Evidence and Group. Sumeet qualified as a physician from the University of Mumbai (India) and holds an MBA from the Saïd Business School, University of Oxford (UK). Prior to joining Analytica Laser, he had gained multi-disciplinary experience working through roles in sales, brand management and strategic planning in companies such as Pfizer and J&J. Sumeet joined Analytica Laser in 2010 and has developed an extensive expertise in real-world evidence strategies and access throughout Europe. At ANALYTICA LASER, he has set up real world research platforms for complex study programs in many therapy areas and has also consulted for clients on projects in the areas of real-world research, evidence generation strategy, strategic positioning and pricing & reimbursement strategy, amongst others. Sumeet brings strategic thinking, insightful perspectives and strong project/program management skills to the projects that he contributes to. He is a senior member of the decision analytics team. -- Artak Khachatryan is Sr. Director, Pharmacoepidemiology in Analytica Laser, Certara’s Evidence and Access Group. Artak joined Analytica Laser in 2010 to participate in the conduct of the International Study of Insulin & Cancer, for the UK. He then directed an international observational study on the relative effectiveness of atrial fibrillation treatments, recruiting in Germany, USA, Spain & Italy. He is the senior epidemiologist on several projects, including an international cohort study on the relative effectiveness of intensive therapies in diabetes, conducted in the UK, Spain, Belgium and France. Artak is a qualified general surgeon. He completed his PhD in Epidemiology at University College of London.

Recent Posts

The Expanding Role of Natural History Studies in Drug Development

Natural history studies follow a group of people over time who have or are at risk of developing a specific disease. This type of study is an important tool in modern drug development and in assessing new health technologies by payers. This is especially true for rare diseases or diseases with high, unmet medical need […]

Read More